Evaluate Safety and Tolerability of RX001 in Patients With KRAS Mutant Advanced NSCLC

NCT06934590 · clinicaltrials.gov ↗

PHASE1

Phase

NOT_YET_RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG: RX001

Sponsor

GeneCraft Inc.